Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy.

López IH, Parada D, Gallardo P, Gascón M, Besora A, Peña K, Riu F, Arquez Pianetta M, Abuchaibe O, Torres Royò L, Arenas M.

Rep Pract Oncol Radiother. 2017 May-Jun;22(3):251-257. doi: 10.1016/j.rpor.2017.02.003. Epub 2017 Apr 26.

PMID:
28479874
2.

Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.

Chang L, Ni J, Beretov J, Wasinger VC, Hao J, Bucci J, Malouf D, Gillatt D, Graham PH, Li Y.

Sci Rep. 2017 Feb 22;7:41834. doi: 10.1038/srep41834.

3.

Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.

Gabriele D, Jereczek-Fossa BA, Krengli M, Garibaldi E, Tessa M, Moro G, Girelli G, Gabriele P; EUREKA-2 consortium.

Radiat Oncol. 2016 Feb 24;11:23. doi: 10.1186/s13014-016-0599-5.

4.

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.

Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG.

Front Oncol. 2016 Feb 16;6:24. doi: 10.3389/fonc.2016.00024. eCollection 2016. Review.

5.

RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.

Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH.

BMC Cancer. 2014 Nov 4;14:808. doi: 10.1186/1471-2407-14-808.

6.

High-risk prostate cancer-classification and therapy.

Chang AJ, Autio KA, Roach M 3rd, Scher HI.

Nat Rev Clin Oncol. 2014 Jun;11(6):308-23. doi: 10.1038/nrclinonc.2014.68. Epub 2014 May 20. Review.

7.

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):848-53. doi: 10.1016/j.ijrobp.2013.04.043. Epub 2013 Jun 5.

8.

Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.

Verhoven B, Yan Y, Ritter M, Khor LY, Hammond E, Jones C, Amin M, Bahary JP, Zeitzer K, Pollack A.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):317-23. doi: 10.1016/j.ijrobp.2013.01.016. Epub 2013 Mar 6.

9.

Systematic review of hypofractionated radiation therapy for prostate cancer.

Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB.

Cancer Treat Rev. 2013 Nov;39(7):728-36. doi: 10.1016/j.ctrv.2013.01.008. Epub 2013 Mar 1. Review.

11.

Tissue biomarkers for prostate cancer radiation therapy.

Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL.

Curr Mol Med. 2012 Jul 1;12(6):772-87. Review.

12.

Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.

Bonkhoff H.

Prostate Cancer. 2012;2012:593241. doi: 10.1155/2012/593241. Epub 2011 Sep 8.

13.

The AR dependent cell cycle: mechanisms and cancer relevance.

Schiewer MJ, Augello MA, Knudsen KE.

Mol Cell Endocrinol. 2012 Apr 16;352(1-2):34-45. doi: 10.1016/j.mce.2011.06.033. Epub 2011 Jul 12. Review.

14.

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.

Gao R, Price DK, Dahut WL, Reed E, Figg WD.

Cancer Biol Ther. 2010 Jul 1;10(1):13-8.

Supplemental Content

Support Center